The update, provided at a conference called IDWeek 2017, follows on from the successful phase III clinical trial of the drug for people with acute bacterial skin and skin structure infections (ABSSSI).
Researchers found there was a 100% survival rate among rats with the infection that were treated with Motif’s iclaprim antibiotic. The drug also helped suppress toxin production.
iclaprim has been granted orphan drug status for the treatment of cystic fibrosis patients with staphylococcus aureus pneumonia, which means the medication could qualify for various development incentives including tax credits.
“Staphylococcus aureus is a common cause of pneumonia in patients with cystic fibrosis and we do not believe that any antibiotic has been approved for this indication,” said David Huang, the chief medical officer of Motif.
“Some 80% or more of patients with cystic fibrosis die as a result of respiratory infections caused by a variety of bacteria, and MRSA infections have been growing in recent years.
“The encouraging new data presented today support developing iclaprim as a potential treatment option for MRSA infections in patients with cystic fibrosis, and iclaprim was recently granted orphan drug designation in the US for Staphylococcus aureus lung infections in this patient group."